Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody.
Is Hemab Therapeutics Holdings, Inc. Common Stock stock overvalued or undervalued in 2026?
As of November 3, 2026, Hemab Therapeutics Holdings, Inc. Common Stock (COAG) trades at $43.10 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Hemab Therapeutics Holdings, Inc. Common Stock
Market cap $2B · 52 weeks $25 – $55 (22% below the high) · P/E no earnings · Dividend none · Next earnings November 10, 2026 · expected EPS -$0.50 · Closing price, Nov 3 · accounts published Aug 11.
- Valuation: P/E — (no earnings).
- Balance sheet: Debt/Equity 0.00 (solid).
- Earnings: Next.
Where would it trade at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 0.0%, fails.
- Market cap / Cash 6.4×, fails.
- Cash Runway 36 months, passes.
- Total Debt 0.0×, passes.
- Annual cash burn $2.24, info.
Against its peers (reference peers) — Hemab Therapeutics Holdings, Inc. Common Stock: P/E —; EV/EBITDA —; ROIC -10.9%; $2.0B. Vericel Corporation (P/E 87.8×; EV/EBITDA 52.6×; ROIC 3.8%; $2.1B), Lakefront Biotherapeutics N.V. (P/E 3.9×; EV/EBITDA 5.2×; ROIC 11.6%; $2.1B), Aurinia Pharmaceuticals Inc. (P/E 7.2×; EV/EBITDA 11.3×; ROIC 20.9%; $2.2B).
Profitability
| Return on Equity | -36.64% |
| Return on Invested Capital | -10.91% |
| Return on Assets | -10.01% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 35.85 |
Price Performance
| 1 month | +40.90% |
| 3 months | -17.37% |
Related companies: IRON · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of COAG: Financials · Valuation · Estimates · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks